MVP
vs
S&P/ASX 300

Over the past 12 months, MVP has significantly outperformed S&P/ASX 300, delivering a return of 48% compared to the S&P/ASX 300's 10% growth.
Stocks Performance
MVP vs S&P/ASX 300
Performance Gap
MVP vs S&P/ASX 300
Performance By Year
MVP vs S&P/ASX 300
Medical Developments International Ltd
Glance View
Medical Developments International Ltd. engages in the manufacture and distribution of pharmaceutical drugs, medical, and veterinary equipment. The company is headquartered in Melbourne, Victoria and currently employs 68 full-time employees. The company went IPO on 2003-12-15. The firm is focused on manufacturing and distributing pharmaceutical drugs, and medical and veterinary equipment. The firm operates through three segments: Pharmaceuticals, Medical Devices and Veterinary Products. The Pharmaceuticals segment is engaged in the sale of Penthrox primarily within Australia, New Zealand, Europe and the United Kingdom, and some sales in the Middle East, Asia and South Africa. The Medical Devices segment is engaged in the sale of medical devices, particularly the Space Chamber and Breath-Alert PeakFlow meters, primarily within Australia, the United Kingdom/Europe, North America, and some sales in Asia and New Zealand. The Veterinary Products segment is engaged in the sale of veterinary products within Australia, Europe, and Asia.
